First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases. Headquartered in San Diego, California, the company was spun off from AnaptysBio in April 2026 to independently advance its immunology pipeline. Its lead clinical programs include ANB033, a CD122 antagonist in Phase 1b development for celiac disease and eosinophilic esophagitis, and rosnilimab, a pathogenic T cell depleter that has completed Phase 2b trials for rheumatoid arthritis. The company's pipeline also features ANB101, a BDCA2 modulator in Phase 1a testing. First Tracks Biotherapeutics operates as a single business segment dedicated to the research and development of protein-based therapeutics.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!